BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 18, 2008
View Archived Issues
Genzyme Seeks Mozobil Nod in Lymphoma, Multiple Myeloma
Cambridge, Mass.-based Genzyme Corp. submitted marketing applications in the U.S and Europe for its lymphoma and multiple myeloma treatment Mozobil (plerixafor), a small-molecule CXCR4 chemokine receptor antagonist. (BioWorld Today)
Read More
$30M Fund Would Aid Aussie Academics, Spur Spinouts
Read More
U.S. Biosimilar Debate Crucial to Worldwide Biotech Industry
Read More
India: Moving from Services to Sustainable Innovation
Read More
Elan Rises on Phase II Data in Alzheimer's Disease
Read More
Japanese Partnerships Offer Opportunities, Challenges
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Financings Roundup
Read More